To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion. The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice. No therapeutic intervention will be administered to patients in this study.
Study Type
OBSERVATIONAL
Enrollment
150
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking University International Hospital
Beijing, Beijing Municipality, China
ORR
Percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR);
Time frame: 15 years
CRR
Complete response rate
Time frame: 15 years
Duration of response (DOR)
Time from first response(PR or CR) to disease progression or death from any cause.
Time frame: 15 years
Progression-Free Survival (PFS)
PFS is defined as the time from the Relmacabtagene Autoleucel infusion date to the date of disease progression per Lugano classification or death from any cause.
Time frame: 15 years
Overall Survival (OS)
OS is defined as the time from Relmacabtagene Autoleucel infusion to the date of death from any cause.
Time frame: 15 years
Adverse events (AEs)
Types, frequency, and severity of adverse events and laboratory anomalies Physiological parameter
Time frame: 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.